Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.5500
-0.0100 (-1.79%)
At close: Mar 27, 2026
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 2.27 billion as of March 27, 2026. Its market cap has decreased by -8.33% in one year.
Market Cap
2.27B
Enterprise Value
2.51B
Revenue
718.98M
Ranking
n/a
PE Ratio
49.42
Stock Price
0.55
Market Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 2.27B, a decrease of -54.55%. That is a compound annual growth rate of -10.91%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 2.27B | 10.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Antengene Corporation | 3.28B |
| Medtide | 3.18B |
| Jiangsu Recbio Technology | 2.52B |
| SinoMab BioScience | 2.45B |
| Frontage Holdings | 2.31B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.92B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 1.87B |
| HighTide Therapeutics | 1.74B |